SpliSense

SpliSense to Present SPL84 Pre-clinical and Clinical data at the North American Cystic Fibrosis Conference in Boston, MA held on Sept 25-28th, 2024. Please meet our team and visit SpliSense posters (#166, 276-277, 302) for further scientific and clinical discussions.

Please join SpliSense management team at the ECFS meeting. On Thursday June 6th, we will be presenting SpliSense’s  SPL84  clinical program and additional preclinical data in 3 oral presentations and a poster presentation.  Presentation numbers: S01 Symposium 01, WS05.04, WS06.02, EPS4.03 Pls join us! 

We are excited to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to our SPL84 , ASO for CF patients treatment . Fast Track Designation for SPL84 is an important acknowledgement by the FDA of the critical need to find an effective treatment for CF patients carrying the 3849+10 kilobase (Kb) C->T mutation, a serious and life-threatening condition with poor treatment options. The recent IND clearance we received from the FDA together with this Fast Track designation for SPL84, currently being evaluated in a global Phase 2 study, will allow us to expedite the development of a potentially life-changing treatment for people with CF carrying the 3849+10 Kb C->T mutation, and expand our unique technology to additional pulmonary indication where there is a significant unmet need. https://lnkd.in/dxcxx9fd

We are excited to share that we have received a FDA approval and IND clearance to initiate phase 2 with our SPL84 ASO for the treatment of CF patients carrying unmet 3849 mutation. This is accommodated by a secured funding from our current investors mainly CFF, IBF , CBG and Integra holdings. This is a significant and exciting accomplishment for SpliSense, as a ASOs pulmonary focused company with a diverse and promising pipeline for the treatment of pulmonary diseases.   https://lnkd.in/d7nPR3cE

We are grateful for the Cystic Fibrosis Foundation (CFF) financial support aiming to advance SPL84 in the clinic by supporting the phase 2 global study. We are excited to expand our work and collaboration with the CFF, aiming to provide innovative, promising and hopefully more effective treatments for CF patients in great need. The CFF support and expertise are instrumental for SpliSense success advancing it ASO platform technology for diverse CF mutations.   https://lnkd.in/dEh8mjTu  

SpliSense to Present SPL84 Phase 1 Clinical Trial data as well as SPL 84 safety and lung distribution at the North American Cystic Fibrosis Conference in Phoenix, Arizona held on November 2-4, 2023 Please join our CEO Dr. Gili Hart at the upcoming NACFC. Dr. Hart will present SPL84, a clinical stage AntiSense Oligonucleotide (ASO) for the treatment of CF patients carrying the 3849 mutation, in 3 oral plenary and symposium sessions. Please visit SpliSense posters for further scientific and clinical discussions.